SUMMARY Eighteen patients with fulminant liver failure were studied, 10 with normal renal function (group A) and eight with renal failure (group B , plasma creatinine >200 [tmol/l). Renal function was assessed by standard clearance techniques and patients in group B had a marked reduction compared with group A in both renal plasma flow and glomerular filtration rate. Raised plasma renin activity was observed in both groups, but levels in group B were significantly higher than in group A. Renal prostacyclin production was estimated by radioimmunoassay (RIA) of 6-keto-prostaglandin Fla in urine, and the excretion rate was markedly increased in group A as compared with nine healthy controls, but was low in group B. The plasma concentrations of 6-ketoprostaglandin Fia and thromboxane B2 were similar in groups A and B and were both significantly higher than in controls. Haemodynamic measurements showed a high cardiac output with low vascular resistance and mean arterial pressure within normal limits in both groups. The pulse pressure, however, was significantly higher in group B than in group A. In conclusion, patients in FHF with renal failure have marked renal vasoconstriction with increased plasma renin activity and reduced renal prostaglandin excretion indicative of an imbalance between vasoactive forces.
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HAEMODYNAMIC MEASURMENTS
All patients had a high cardiac output and no differences were found between the two groups ( Table 2 ). The increase in cardiac output was associated with reduced total peripheral vascular resistance and mean arterial pressure was maintained within normal limits in both groups studied. Of interest, patients in group B showed higher systolic blood pressure than group A, while diastolic pressure was similar in both groups. Thus, group B characteristically exhibited higher pulse pressure than group A. Prostacyclin is a potent vasodilator able to modulate vascular reactivity to pressor hormones.8 After its local synthesis, prostacyclin is readily hydrolysed to 6-keto-PGF1a and then enzymatically transformed to several metabolites. Urinary 6-ketoPGFia is believed to be mainly of renal origin while further metabolic products would reflect systemic prostacyclin synthesis. 9 We found that the excretion rate of urinary 6-keto-PGFia is highly stimulated in FHF without renal failure, but not in patients with renal failure. On the other hand, plasma renin activity was increased in all patients,"' with those in renal failure showing highest levels. These findings suggest that enhanced renal prostacyclin synthesis in FHF would counteract vasoconstrictor forces in an attempt to maintain renal function within normal limits.
The fact that urinary 6-keto-PGFia is reduced in patients with renal failure may be interpreted either as a decrease in renal prostacyclin synthesis or as an impairment of its excretion because of a reduced glomerular filtration rate. The possible contribution of preglomerular sources to urinary 6-keto-PGFIa is not well established. Nevertheless, studies have shown that sulindac inhibits systemic prostacyclin synthesis without changing urinary 6-keto-PGF1a," while frusemide increases urinary excretion without systemic changes,'2 suggesting that urinary 6-ketoPGFia mainly derives from intrarenal sources. On the other hand, prostacyclin was shown to represent the major arachidonic acid product synthesised by medullary microsomes of human kidney and, in addition, biosynthetic capacity is five to 20 times higher in medulla than in cortex.'3 These data would suggest that prostacyclin production is comparatively higher within the tubules than in preglomerular vessels. Assuming that factors stimulating cortical prostacyclin synthesis would also stimulate production within the tubules, it may be concluded that patients in renal failure showed the highest constrictor stimuli without an appropriate response in renal prostacyclin synthesis. An imbalance between vasoactive forces would lead to renal failure, as previously suggested in patients with decompensated cirrhosis. 4 Urinary excretion of TXB2 also varied in the groups studied with a similar pattern to that of 6-keto-PGFi,a, although stimulation in group A was less marked. This finding may be dependent on the renal activation of the arachidonic acid metabolic cascade yielding different products. The present results differ from those observed in cirrhosis with renal failure, where raised urinary TXB2 excretion was observed."'4 This may be related to a more severe reduction of renal plasma flow and glomerular filtration rate in patients with FHF compared to those with cirrhosis.
The plasma concentrations of both 6-keto-PGF1a and TXB2 were similarly increased in the two groups of patients studied, irrespective of their renal function. This suggests the ability to synthesise prostaglandins in peripheral vessels is not impaired in patients with renal failure. Increased plasma prostaglandin metabolites may be the result of an enhanced platelet wall interaction in FHF, consistent with the altered platelet aggregation and adhesiveness in this condition.'9'6 Reduced renal prostaglandin synthesis is thus more likely to depend on local causes acting within the kidney.
Finally, both groups of patients exhibited a hyperdynamic circulation with high cardiac output and low systemic vascular resistance, as previously observed.'7'8 Hyper-reninism is probably a homeostatic response to reverse a decrease in peripheral vascular resistance. '°" Regional distribution of cardiac output was different between the two groups at least in regard to renal blood flow, which was markedly reduced in patients with renal failure. Such a reduction in the presence of a high cardiac output would suggest the existence of areas of very low vascular resistance that would not occur to the same extent in patients with preserved renal function. In addition, in this study, renal failure was associated with a wide pulse pressure as a result of raised systolic pressure. This finding suggests there is a low arterial elasticity probably caused by raised vascular tone and, in fact, these patients showed highest plasma renin activity. Taken together, these data might indicate the existence of areas of arteriovenous shunt in patients with renal failure and, additionally, a generalised stimulation of vasoconstrictor systems as a homeostatic response.
In summary, patients with FHF who developed renal failure showed marked renal vasoconstriction and reduced renal synthesis of prostacyclin. As plasma renin activity was highest in these patients, an imbalance between vasoactive factors may be involved in the pathogenesis of renal failure. 
